These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 31533521

  • 1. De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.
    Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y.
    Leuk Lymphoma; 2020 Feb; 61(2):328-336. PubMed ID: 31533521
    [Abstract] [Full Text] [Related]

  • 2. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab.
    Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, Ennishi D, Tamaru JI, Ishizawa K, Kashimura M, Kagami Y, Sunami K, Yamane H, Nishikori M, Kosugi H, Yujiri T, Hyo R, Katayama N, Kinoshita T, Nakamura S.
    Ann Oncol; 2011 Jul; 22(7):1601-1607. PubMed ID: 21199885
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse.
    Oka S, Ono K, Nohgawa M.
    Pathol Oncol Res; 2020 Jul; 26(3):1843-1850. PubMed ID: 31768966
    [Abstract] [Full Text] [Related]

  • 5. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
    Zhao P, Li L, Zhou S, Qiu L, Qian Z, Liu X, Meng B, Zhang H.
    Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
    [Abstract] [Full Text] [Related]

  • 6. Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation.
    Ge J, Xia Y, Sun Z, Zhang L, Li X, Li L, Wang X, Zhang X, Li Z, Nan F, Wan W, Xu D, Ding J, Fu X, Zhang M.
    Leuk Lymphoma; 2022 Jun; 63(6):1369-1374. PubMed ID: 34989286
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
    Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, Khoury JD, Hu S, Xu J, Loghavi S, Hu B, Oki Y, Li S.
    Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
    [Abstract] [Full Text] [Related]

  • 10. CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China.
    Yin T, Qi L, Zhou Y, Kong F, Wang S, Yu M, Li F.
    J Int Med Res; 2022 Sep; 50(9):3000605221110075. PubMed ID: 36112929
    [Abstract] [Full Text] [Related]

  • 11. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with de novo diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma.
    Uryu H, Mishima Y, Tsuyama N, Yokoyama M, Nishimura N, Fukuta T, Shirouchi Y, Okabe T, Inoue N, Takeuchi K, Terui Y.
    Leuk Lymphoma; 2021 Sep; 62(9):2141-2150. PubMed ID: 33749498
    [Abstract] [Full Text] [Related]

  • 12. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H, Fan L, Fu D, Lin Q, Shen J.
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [Abstract] [Full Text] [Related]

  • 13. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
    Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Hirano M.
    Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
    [Abstract] [Full Text] [Related]

  • 14. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D, de Nully Brown P, Loft A, Iyer V, Johnsen HE, Savage KJ, Connors JM, Hutchings M.
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [Abstract] [Full Text] [Related]

  • 15. [CD5-positive DLBCL: molecular basis and treatment strategies].
    Miyazaki K.
    Rinsho Ketsueki; 2015 Aug; 56(8):1038-44. PubMed ID: 26345564
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
    Weng H, Shrestha PR, Hong H, Chen Z, Yu L, Yao Y, Zhang Z, Zou L, Zhu B, Zhou H, Liu X, Liu Y, Guo H, Huang H, Lin T.
    Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
    [Abstract] [Full Text] [Related]

  • 18. Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era.
    Lehners N, Krämer I, Schwarzbich MA, Ho AD, Witzens-Harig M.
    Leuk Lymphoma; 2016 Nov; 57(11):2619-25. PubMed ID: 26999040
    [Abstract] [Full Text] [Related]

  • 19. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
    Jurczak W, Ochrem B, Giza A, Zimowska-Curyło D, Górecki T, Boguradzki P, Knopińska-Posłuszny W, Stella-Hołowiecka B, Walewski J, Joks M, Wróbel T, Zaucha JM.
    Pol Arch Med Wewn; 2015 Nov; 125(10):741-8. PubMed ID: 26334344
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C, Rodríguez AJ, Gutiérrez G, Díaz FJ, González-Barca E, de Oña R, Grande C, Sancho JM, García-Álvarez MF, Sánchez-González B, Peñalver FJ, Cannata J, Espeso M, Requena MJ, Gardella S, Durán S, González AP, Alfonso A, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea GELTAMO Spanish Cooperative Group.
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.